Eficacia y seguridad de la combinación de fexofenadina con montelukast en el tratamiento de la rinitis alérgica
Efficacy and safety of combined therapy of fexofenadine and montelukast for the treatment of allergic rhinitis
Patricia O´farrill-Romanillos; Magda Luz Atrián-Salazar; Leonel González-González; Diana Molina-Vélez; Elizabeth Meda-Monzón; Concepción García-Morales; Vanessa Cohen-Muñoz; Gabriela Sánchez-Casado
Resumen
El propósito de este trabajo fue revisar la literatura científica que evalúa la eficacia y seguridad de las monoterapias de fexofenadina y montelukast, la terapia combinada (fija o en asociación) de montelukast - fexofenadina, así como de montelukast con otros antihistamínicos de segunda generación en el tratamiento de la rinitis alérgica. Se realizó una estrategia de búsqueda bibliográfica de múltiples etapas, en donde se identificaron estudios basados en ensayos clínicos y estudios no aleatorizados (ensayo controlado no aleatorizado, controlado antes-después, de series de tiempo interrumpidas, con controles históricos, de cohorte, de casos y controles, estudio transversal, y series de casos) en pacientes con rinitis alérgica, en las bases de datos MEDLINE/ PubMed, Scopus, Web of Science, Biblioteca Cochrane, Redalyc y Colección BVS y debido a la cantidad de resultados obtenidos se incluyó la búsqueda en Hinari. Con base en esta revisión se concluye que las combinaciones de antihistamínicos de segunda generación y antagonistas de leucotrienos y, en particular, la combinación fija de fexofenadina – montelukast es eficaz, segura y favorece la adherencia al tratamiento, y a largo plazo también ayuda a alcanzar el objetivo terapéutico.
Palabras clave
Abstract
The purpose of this work was to review the scientific literature that evaluates the efficacy and safety of monotherapies of fexofenadine and montelukast, the combined therapy (fixed-dose or separate drug combinations) of montelukast-fexofenadine, as well as the use of montelukast together with other second-generation antihistamines in the treatment of allergic rhinitis. A multistage literature search strategy was designed, including clinical trials and non-randomized studies (non-randomized controlled trial, controlled before-after study, interrupted time series study, historical control study, cohort study, case-control study, crosssectional study, and case series) evaluating patients with allergic rhinitis. The databases MEDLINE/PubMed, Scopus, Web of Science, Cochrane Library, Redalyc, BVS Collection, and, due to the number of results obtained, Hinari were included. Based on this review, the conclusion is that the combinations of secondgeneration antihistamines with leukotriene antagonists and, in particular, the fixed combination of fexofenadine-montelukast are effective, safe and promote treatment adherence. In the long term, they also help achieve therapeutic goals.
Keywords
References
1. Organización Mundial de la Salud (OMS). OMS - Enfermedades respiratorias crónicas. WHO, 2016 [Internet]. Disponible en: https://www.who.int/respiratory/about_topic/es/. Consultado elThu Dec 05 2019 00:00:00 GMT-0300 (Horário Padrão de Brasília)
2. World Health Organization (WHO). Action plan of the Global Alliance against Chronic Respiratory Diseases. Action Plan 2008-2013. Italy: World Health Organization, (WHO); 2008. p. 34.
3 Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125(2):S103-15.
4. Akdis CA, Hellings PW, Agache I, eds.; European Academy of Allergy and Clinical Immunology (EAACI). Global atlas of allergic rhinitis and chronic rhinosinusitis. Zurich: EAACI; 2015.
5. U.S. National Library of Medicine (NLM). Enciclopedia médica. Rinitis alérgica. U.S. National Library of Medicine (NLM); 2018.
6. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med. 2015;372(5):456-63. doi: 10.1056/NEJMcp1412282.
7. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, BosnicAnticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guideline – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8.
8. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55(2):116-34.
9. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63(Suppl. 86):8-160. doi:10.1111/j.1398- 9995.2007.01620.x
10. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108(1 Suppl):S45-53.
11. Camelo-Nunes IC, Solé D. Rinite alérgica: indicadores de qualidade de vida. J Bras Pneumol. 2010;36(1):12-33.
12. Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am J Ther. 2016;23(6):e1568-e1578.
13. Small P, Keith PK, Kim H. Allergic rhinitis. Allergy, Asthma Clin Immunol. 2018;14(2):51. doi:10.1186/s13223-018-0280-7.
14. México, Instituto Mexicano del Seguro Social. Diagnóstico y Tratamiento de Rinitis Alérgica. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica. [Internet] México, IMSS; 2017. Disponible en: http://www.imss.gob.mx/profesionalessalud/gpc.
15. Mösges R, Lehmacher W, Pasch N, Vent J. Assessment of the antiobstructive effect of fexofenadine on nasal allergy challenge in patients with seasonal allergic rhinitis. Asian Pacific J Allergy Immunol. 2009;27(4):1-10.
16. Escuela Andaluza de Salud Pública. Nuevos tratamientos del asma: antagonistas de los leucotrienos. Bol Ter Andal. 1999;15(6):21-2.
17. Walekar A, Chodankar D, Naqvi M, Trivedi C. Assessment of Bioequivalence of Fexofenadine and Montelukast Fixed Dose Combination Tablet Versus Separate Formulations of the Individual Components at the Same Dose Levels. Indian J Pharm Sci. 2016;78(5):651-6.
18. Baños ZM, Somonte ZDE, Morales PV. Leucotrienos y antileucotrienos en medicina basada en la evidencia. Rev Mex Patol Clin Med Lab. 2015;62(3):157-62.
19. Takahashi G, Matsuzaki Z, Okamoto A, Ito E, Matsuoka T, Nakayama T, et al. A randomized control trail of stepwise treatment with fluticasone propionate nasal spray and fexofenadine hydrochloride tablet for seasonal allergic rhinitis. Allergol Int. 2012;61(1):155‑62.
20. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. Onset of action of loratadine / montelukast in seasonal allergic rhinitis patients exposed to grass pollen. Arzneimittelforschung. 2010;60(5):249-55.
21. Yamamoto H, Yamada T, Sakashita M, Kubo S, Susuki D, Tokunaga T, et al. Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Allergy Asthma Proc. 2012;(c):17-22.
22. Kim MK, Lee SY, Park HS, Yoon HJ, Kim SH, Cho YJ, et al. A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis. Clin Ther. 2018;40(7):1096-107.
23. Ciebiada M, Gorska-Ciebiada M, Barylski M, Kmiecik T, Gorski P. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25(1):1-6.
24. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5):917-22.
25. Gupta V, Matreja PS. Efficacy of montelukast and levocetirizine as treatment for allergic rhinitis. J Aller Ther. 2010;1:103. doi: 10.4172/2155-6121.1000103.
26. Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant stherapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718-23. doi:10.1002/lary.20941.
27. Naik M, Nayak A, Khandeparkar P, Mukaddam Q. Efficacy and safety of montelukast plus fexofenadine fixed dose combination in allergic rhinitis: Results of post-marketing study in India. Indian Medical Gazette. 2013;8:314-8.
28. Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar S, Wankhede S. Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian J Pharmacol. 2016;48(6):649-53. doi:10.4103/0253-7613.194854.
29. Ciebiada M, Gorska-Ciebiada M, Gorski P. Fexofenadine with either montelukast or a low-dose inhaled corticosteroid (fluticasone) in the treatments of patients with persistent allergic rhinitis and newly diagnosed asthma. Arch Med Sci. 2009;5:564-9.
30. González-González E, García-Morales C, Molina-Vélez D, et al. Protocolo de revisión sistemática de literatura sobre la eficacia y seguridad de las monoterapias de fexofenadina y montelukast, y la terapia de montelukast en combinación con fexofenadina u otros antihistamínicos de segunda generación para el tratamiento. 2019. [Internet]. Disponible en: https://osf.io/mfzdp/. Consultado el 24/02/2020.
31. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol. 2010;24:3-8.4.
Submitted date:
01/05/2021
Accepted date:
07/11/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email